2025년 03월 06일 목요일
 
 
  현재위치 > 뉴스지닷컴 > Science & Technology

랜섬웨어부터 돼지도살까지... 노련해진 사기행각

 

정치

 

경제

 

사회

 

생활

 

문화

 

국제

 

과학기술

 

연예

 

스포츠

 

자동차

 

부동산

 

경영

 

영업

 

미디어

 

신상품

 

교육

 

학회

 

신간

 

공지사항

 

칼럼

 

캠페인
한살림 ‘우리는 한쌀림’ 쌀 소비 캠페인 시...
1000만원짜리 인공와우, 건강보험 지원 ‘평...
- - - - - - -
 

Boehringer Ingelheim Enters Global Licensing Agreement To Develop And Commercialize Innovative Antibodies From A*Star For Targetted Cancer Therapies

Boehringer Ingelheim gains exclusive global rights to a panel of cancer-specific antibodies to enable the development of targeted cancer therapies
뉴스일자: 2022-06-03

INGELHEIM, GERMANY & SINGAPORE-- June 03, 2022 -- Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR. Boehringer Ingelheim aims to use these antibodies to direct therapeutic effector mechanisms such as antibody-drug conjugates (ADCs) and T-cell engagers exclusively to tumor cells, and to that end develop a range of highly targeted cancer treatments.

“Boehringer Ingelheim believes that these promising antibodies in-licensed from A*STAR will help us advance potent therapeutic candidates against key molecular cancer targets,” says Clive R. Wood, Senior Corporate Vice President and Global Head of Discovery Research at Boehringer Ingelheim and continues: “We look forward to developing these assets for a broad range of cancers with the goal to deliver breakthrough opportunities for patients.”

Boehringer Ingelheim is pioneering a range of versatile therapeutic platforms in order to develop innovative medicines that target the tumor directly (tumor cell-directed therapies) or that enable the immune system to target the tumor (immune cell-targeted therapies). One tumor cell-directed modality is antibody drug conjugates, which allows for delivery of toxins directly into tumor cells. Another is T-cell engagers facilitating direct contact between T-cells and tumor cells, leading to T-cell-mediated killing of the tumor. Both technologies are directed towards markers on the surface of cancer cells, also known as antigens, in order to attack tumor cells but spare healthy tissues.

The innovative antibodies from A*STAR can potentially enable the development of safer, more efficacious therapies as they selectively bind to antigens that are highly expressed on tumor cells but are absent on normal healthy tissues.

Under the terms of the agreement, Boehringer Ingelheim will be responsible for further research, preclinical and clinical development as well as commercialization of targeted cancer therapies using the antibodies from A*STAR. A*STAR may receive payments totalling >100 million EUR in upfront and success-based development and commercialization milestones.

The technology used to identify the unique A*STAR antibodies resulted from a multi-institutional collaboration in Singapore. A*STAR’s Genome Institute of Singapore (GIS) and Institute of Bioengineering & Bioimaging (IBB) generated antibodies which exclusively target antigens that were initially identified from gastric cancer cells. Experimental Drug Development Centre (EDDC), Singapore’s national platform for drug discovery and development hosted by A*STAR, then optimized the antibodies and confirmed their applicability to a range of other solid cancers. EDDC also demonstrated the utility of these antibodies in directing different therapeutic modalities selectively to cancer cells.

Professor Damian O‘Connell, Chief Executive Officer of EDDC, says, “As Singapore’s national drug discovery and development platform, EDDC is proud to translate great science in Singapore into valuable assets that can enable the precise treatment of cancer. We believe that Boehringer Ingelheim, with its broad expertise and technologies, is the right partner to maximize the potential of these antibodies for the development of safer, more targeted therapies for cancer patients.”

Professor Tan Sze Wee, Assistant Chief Executive (Enterprise) of A*STAR, says, “These antibodies were developed in Singapore through close collaboration across multiple institutions. There was also strong support by the Singapore Gastric Cancer Consortium. The agreement is testament to the best-in-class research taking place in Singapore. Cancer is a devastating disease, and we hope the fruits of our research can improve patient outcomes.”



 전체뉴스목록으로

Esri Advances Secure Drone Solutions with Blue UAS Cleared, Federally Approved Drone
NTT DATA and Palo Alto Networks Enhance Private 5G Security for Industrial Deployments
Lenovo Pioneers More Personalized, Integrated, and Innovative Hybrid AI Technology at MWC 2025
CareDx Announces Study Showing AlloSeq cfDNA Highly Accurate in Detecting Rejection in Organ Transplant Patients
ICC Arbitral Tribunal Rules in Favor of AOP Health in Arbitration Proceedings Pertaining to BESREMi
Geothermal Developer Ignis H2 Energy Raises $12.5M in Series A First Close
UL Solutions Reinforces Leadership in Fire Safety with New, Upgraded Global Fire Science Center of Excellence

 

Energy Vault Begins Construction of Battery Energy Storage Deployment ...
NTT DATA Launches Smart AI Agent to Accelerate Generative AI Adoption ...
Ferrer is the Highest-performing Pharmaceutical Company in the World f...
Parse Biosciences Launches 5 Million Cell Evercode WT Penta Kit for Si...
Novotech Partners with Wonju Severance Christian Hospital to Drive Cli...
SES Enables Viasat Energy Services’ Asia-Pacific Customer to Experien...
Variational AI Announces Oversubscribed $5.5 Million Financing to Laun...

 


공지사항
알리우브 Alliuv 중문 표기 '阿联备'
오스프롬 Ausfrom 중문 표기 奥斯福牧
에너프롬 Enerfrom 중문 표기 额能福牧
알프롬 Alfrom 중문 표기 阿尔福牧
베네프롬 베네인투 중문 표기 宝乃福牧 宝乃因托
뉴스지 한자 표기에 대만식 음차 표기 '纽斯集 니우시지' 병기
뉴스그룹 정보 미디어 부문 상표등록
알프롬 계열 상표, 상표등록 완료
알뜰건설, 상표등록 완료

 

회사소개 | 인재채용 | 이용약관 | 개인정보취급방침 | 청소년보호정책 | 책임한계와 법적고지 | 이메일주소무단수집거부 | 고객센터

기사제보 이메일 news@newsji.com, 전화 050 2222 0002, 팩스 050 2222 0111, 주소 : 서울 구로구 가마산로 27길 60 1-37호

인터넷뉴스서비스사업등록 : 서울 자00447, 등록일자 : 2013.12.23., 뉴스배열 및 청소년보호의 책임 : 대표 CEO

Copyright ⓒ All rights reserved..